Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

Li, Jian; Nation, Roger L.; Milne, Robert W.; Turnidge, John; Coulthard, Kingsley

doi:10.1016/j.ijantimicag.2004.10.001

Cited by 497 publications

(474 citation statements)

References 153 publications

(318 reference statements)

Supporting

Mentioning

450

Contrasting

Unclassified

Order By: Relevance

“…The drug acts on outer cell membrane of Gram-negative bacteria (GNB) and releases lipopolysaccharides [15]. This in turn results into disruption of cell membrane leading to leakage of cell content, causing cell lysis and finally cell death [16,17]. Within years after the reuse of colistin, there have been reports of colistin-resistant strains [18].…”

Section: Discussionmentioning

confidence: 99%

Colistin Resistance in Carbapenem-Resistant Klebsiella Pneumoniae Strains

Bhaskar

Mulki

Joshi

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: There is an increasing use of colistin consequent to increase in the infections caused by carbapenem-resistant Klebsiella pneumoniae. The present study was conducted to determine the minimum inhibitory concentration (MIC) of colistin and the resistance pattern of colistin in carbapenem-resistant K. pneumoniae (CRKP) strains in our intensive care unit (ICU).Methods: Antibiotic susceptibility testing for other antimicrobial agents was done by Kirby-Bauer disk diffusion method. MIC of colistin was determined by agar dilution method. The results of antibiotic susceptibility testing were interpreted as per Clinical Laboratory Standard Institute guidelines 2016 and MIC of colistin were interpreted as per European Committee on Antimicrobial susceptibility testing. The carbapenem resistance was phenotypically detected by modified hodge test and imipenem/imipenem ethylenediaminetetraacetic acid disk method.Results: Out of 518 K. pneumoniae, 329 were resistant to carbapenems, and 91 isolates showed resistance to colistin. The MIC of colistin ranged between 4 and >512 ug/ml and MIC 90 was 16 ug/L and MIC 50 was 4 ug/ml. A majority of the colistin-resistant isolates were found in multidisciplinary ICU (85/91). Conclusion:The emergence of colistin-resistant strains is a major problem due to limited treatment options for infections caused by CRKP carbapenemase producing K. pneumoniae. Colistin should not be used alone, combination therapy should be preferred.

show abstract

Section: Discussionmentioning

confidence: 99%

Colistin Resistance in Carbapenem-Resistant Klebsiella Pneumoniae Strains

Bhaskar

Mulki

Joshi

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…For example, a revisited toxicity assessment along with the emergence of multi-drugresistant Gram-negative bacteria, prompted the reintroduction of colistin and its derivatives in clinical practice [63]. Among the numerous efforts made to reduce the toxicity of polymyxins, the synthesis of colistin methanesulfonate (CMS), a pro-drug of colistin where the free amino groups are blocked by sulfomethylation, resulted in a reduced in vitro activity along with a dramatically decreased toxicity and avoidance of some local painful, undesirable side effects.…”

Section: Polymyxins and Derivativesmentioning

confidence: 99%

Lipopeptides as anti-infectives: a practical perspective

et al. 2009

View full text Add to dashboard Cite

Abstract:Lipopeptide antibiotics represent an old class of antibiotics that were discovered over 50 years ago, which includes the old polymyxins but also new entries, such as the recently approved daptomycin. They generally consist of a hydrophilic cyclic peptide portion attached to a fatty acid chain which facilitates insertion into the lipid bilayer of bacterial membranes. This review presents an overview of this class of antibiotics, focusing on their therapeutic applications and putting particular emphasis on chemical modifications introduced to improve their activity.

show abstract

“…En el Reino Unido este criterio es ≥ 8 µg/mL (susceptible ≤ 4 µg/mL). 2 Nuestra institución ha incorporado el método E-test para evaluar la susceptibilidad de los aislados ante colistín, un método que permite contar con un valor de CIM y de más fácil aplicación asistencial que la microdilución en caldo 1 . La estrategia por E-test ha sido validada con un alto grado de reproducibilidad y concordancia, aunque con limitaciones en valores extremos 1 .…”

Section: Discussionunclassified

“…En los pacientes sin falla renal en nuestra serie, el promedio diario de dosis utilizado fue de 3,24 mg/kg, inferior al rango 4 a 6 mg/kg propuesto en ese país 16,17 . El no alcanzar una dosis mínima, limita el efecto terapéutico, ya que no permite un efecto bactericida concentración dependiente 2,12 .…”

Section: Discussionunclassified

Colistín en infecciones nosocomiales por bacilos gramnegativos pan-resistentes

et al. 2007

Rev. chil. infectol.

View full text Add to dashboard Cite

Emergence of panresistant gram negative bacilli has lead to the progressive reintroduction of intravenous colistin. Aim: To describe the clinical experience observed with this compound. Methodology: A retrospective analysis was performed for all treatments lasting > 48 hours. Medical records were analyzed to obtain clinical parameters and microbiological data, evaluate clinical response and evolution until discharge. Main results: 24 treatments lasting > 48 hours were applied between June 2005 and September 2006. Intravenous colistin was indicated to treat cases of ventilator-associated (VA) pneumonia (n = 10; 41.7%), abscess or collections (12.5%), bloodstream infections, non-VA pneumonia or urinary tract infections (4.2% each one, respectively). Treatment was initiated on average at 3.2 days (± 2.85) from diagnosis of infection. All courses were microbiologically-guided, and involved P. aeruginosa or A. baumannii isolates. Susceptibility was evaluated by E-test in 11 isolates (MIC 90 3.6 µg/mL, range 0.38 to 4 µg/mL). One isolate was resistant to colistin (9%). A favorable response was observed in 12 treatments (50%) with a relapse in 5 cases (41.7%). Being treated for pneumonia was the only factor associated to failure. (p = 0.04) Eradication was documented in 8 cases (33.3%) and persistence in 11 (45.8%). In 5 cases a microbiological follow-up was not available. Survival at time of discharge was 45.5%. (n = 10) None of the treatment courses was associated with nefrotoxicity. Conclusions: Intravenous colistin is a safe compound useful to treat various nosocomial infections due to pan-resistant gram negative bacilli. Nonetheless, its clinical efficacy is limited, especially among patients treated for nosocomial pneumonia.Key words: colistin, sepsis, Gram negative bacilli, panresistance. Palabras claves: colistín, bacilos gramnegativos, infecciones, pan-resistencia.Los datos epidemiológicos sobre la frecuencia de bacilos gramnegativos multi o pan-resistentes son escasos en el país, debido a que sólo recientemente se ha creado un sistema de vigilancia activo. Se trata, sin embargo, de un hecho progresivo radicado, especialmente, en las unidades de cuidados intensivos de hospitales de la Región Metropolitana. En el Hospital Clínico de la Universidad de Chile, la frecuencia de aislados de A. baumannii o P. aeruginosa pan-resistentes ha aumentado en forma constante desde el año 2004, motivando la importación de colistín para el manejo de estas infecciones.Colistín endovenoso es un fármaco de alto costo, no exento de toxicidad renal y carece de una evaluación rigurosa de su eficacia clínica. Por ejemplo, el costo diario de tratamiento con este antimicrobiano supera los 60 mil pesos chilenos (aproximadamente 120 U$). Habitualmente, los pacientes son tratados por 10 o más días. Introducciónas infecciones nosocomiales son un problema frecuente y se asocian a morbilidad, aumento de los costos y letalidad atribuible. Están asociadas a microorganismos multi o pan-resistentes que limitan, seriamente, las posibilidades de m...

show abstract

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

Cited by 497 publications

References 153 publications

Colistin Resistance in Carbapenem-Resistant Klebsiella Pneumoniae Strains

Colistin Resistance in Carbapenem-Resistant Klebsiella Pneumoniae Strains

Lipopeptides as anti-infectives: a practical perspective

Colistín en infecciones nosocomiales por bacilos gramnegativos pan-resistentes

Contact Info

Product

Resources

About